IO Biotech Inc (OQ:IOBT)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

May 14, 2024 07:55 am ET

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024. “This...

Apr 24, 2024 04:30 pm ET

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s...

Apr 15, 2024 08:30 am ET

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial...

Apr 09, 2024 12:00 pm ET

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine...

Apr 05, 2024 08:30 am ET

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief...

Mar 06, 2024 04:11 pm ET

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American...

Mar 05, 2024 04:40 pm ET

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024 04:05 pm ET

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will...

Dec 21, 2023 08:30 am ET

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial...

Nov 13, 2023 08:12 am ET

IO Biotech Announces 2023 Third Quarter Results

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® technology platform, today reported financial results for the third quarter ended September...

Nov 13, 2023 08:00 am ET

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr....

Nov 10, 2023 08:00 am ET

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced today that it has completed enrollment in the pivotal Phase 3 clinical trial for IO102-IO103, in...

Nov 08, 2023 04:30 pm ET

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event:...

Nov 01, 2023 08:30 am ET

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster presentations at the Society for Immunotherapy of...

Oct 23, 2023 01:00 am ET

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcin

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s Phase 2 basket trial of IO102-IO103 in combination with...

Oct 03, 2023 04:30 pm ET

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced three poster presentations at the Society for Immunotherapy of Cancer’s...

Sep 12, 2023 08:05 am ET

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced that data from a pre-defined interim analysis related to the lung cohort of...

Sep 06, 2023 08:35 am ET

IO Biotech Announces Participation in Upcoming Investor Conferences

Aug 11, 2023 08:30 am ET

IO Biotech Announces 2023 Second Quarter Results

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the second quarter ended June 30, 2023. “We...

Aug 11, 2023 08:05 am ET

IO Biotech Appoints Heidi Hunter to its Board of Directors

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an...

Aug 08, 2023 08:05 am ET

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial of...

Aug 07, 2023 08:30 am ET

IO Biotech, Inc. Announces $75 Million Private Placement Financing

IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement...

Jul 28, 2023 08:05 am ET

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that the University of California Davis Comprehensive Cancer Center...

Jul 25, 2023 04:05 pm ET

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

Jul 18, 2023 04:05 pm ET

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr....

Jun 14, 2023 08:00 am ET

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that it has randomized 225 patients in its global Phase 3 clinical...

Jun 01, 2023 08:30 am ET

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP,...

May 30, 2023 04:35 pm ET

IO Biotech to Present at the Jefferies Healthcare Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy...

May 11, 2023 04:05 pm ET

IO Biotech Announces 2023 First-Quarter Results

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the first quarter ended March 31, 2023. The...

Mar 14, 2023 04:11 pm ET

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the fourth quarter and year-ended December 31,...

Feb 22, 2023 07:00 am ET

IO Biotech to Participate in March 2023 Investor Conferences

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platform, today announced participation in two upcoming investor conferences. Mai-Britt Zocca,...

Jan 23, 2023 08:00 am ET

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel...

Jan 09, 2023 07:05 am ET

IO Biotech Provides Business Update

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update. “Throughout 2022, the team at IO Biotech made major...

Nov 09, 2022 04:07 pm ET

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Ann

IO Biotech (Nasdaq: IOBT), IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, today announced details of the invited oral presentation and two...

Nov 09, 2022 04:05 pm ET

IO Biotech Announces Third Quarter Results for 2022

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ending September 30, 2022....

Nov 03, 2022 08:00 am ET

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients w

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has entered into a fourth clinical trial collaboration and...

Oct 31, 2022 08:00 am ET

IO Biotech to Participate in the Jefferies London Healthcare Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and...

Oct 13, 2022 04:05 pm ET

IO Biotech Announces Appointment of New Chief Financial Officer

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, today announced the appointment of Amy Sullivan as the company’s new Chief Financial...

Oct 05, 2022 08:05 am ET

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced an oral presentation and two poster presentations at the Society for...

Sep 06, 2022 07:30 am ET

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, the company’s President and CEO, will be...

Aug 11, 2022 05:00 pm ET

IO Biotech Announces Second Quarter Results for 2022

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ending June 30, 2022. “We...

Jun 06, 2022 08:00 am ET

IO Biotech to Participate in the 2022 BIO International Convention

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the company will be participating at the 2022 BIO International...

May 26, 2022 05:00 pm ET

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today two poster presentations highlighting clinical trials in progress...

May 23, 2022 08:00 am ET

IO Biotech to Participate in the Jefferies Healthcare Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the Company will be participating in the Jefferies Global...

May 18, 2022 07:00 am ET

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient in its Phase 3 IOB-013 / KN-D18...

May 16, 2022 04:15 pm ET

IO Biotech Announces First Quarter Results for 2022

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ended March 31, 2022. “During our...

Apr 22, 2022 08:33 am ET

IO Biotech Hosting Key Opinion Leader Webinar Series

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it will be hosting a series of key opinion leader (KOL)...

Apr 12, 2022 08:30 am ET

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient, in metastatic non-small cell...

Apr 08, 2022 04:15 pm ET

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today updated efficacy data and subgroup analyses from the MM1636 Phase...

Mar 31, 2022 04:15 pm ET

IO Biotech Announces Year-End Results for 2021

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the year ended December 31, 2021....

Mar 08, 2022 04:30 pm ET

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that an abstract from its MM1636 Phase 1/2 clinical trial evaluating...

Mar 04, 2022 08:00 am ET

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to...

Mar 03, 2022 04:05 pm ET

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors. Mr....

Dec 09, 2021 11:05 am ET

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win® technology, today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial in Nature...

Dec 06, 2021 08:00 am ET

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has entered into a third clinical trial collaboration and...

Nov 09, 2021 11:06 am ET

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, including the exercise in full by the underwriters’ option to purchase 1,072,500 additional shares of...

Nov 04, 2021 11:52 pm ET

IO Biotech, Inc. Announces Pricing of Initial Public Offering

IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $100.1...

Ad blocking detected

IO Biotech Inc (OQ:IOBT)

Business Focus: Biotechnology & Medical Research